Form 4: Phathom Pharmaceuticals Director Mark Stenhouse Reports Stock and Option Transactions

Director Mark Stenhouse reports acquisition of restricted stock units and stock options in Phathom Pharmaceuticals.

Summary

• Mark Stenhouse, a director at Phathom Pharmaceuticals, reported transactions involving the company's securities.
• On May 23, 2024, Stenhouse acquired 10,500 shares of common stock in the form of Restricted Stock Units (RSUs) and disposed of 19,500 shares.
• Additionally, Stenhouse acquired options to purchase 17,500 shares of common stock at an exercise price of $10.30, expiring on May 22, 2034.
• The RSUs vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.
• The stock options also vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of RSUs and options is generally positive, but the disposal of shares is slightly negative.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Negatives

• The disposal of 19,500 shares by Stenhouse could be interpreted negatively by some investors.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Phathom Pharmaceuticals' stock.
• Changes in market conditions or company performance could impact the value of these securities.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the director's continued service on the board, suggesting an expectation of ongoing involvement.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• Shareholders may be interested in the transactions of company directors as an indicator of management's confidence in the company.

Key Dates